CD2BP2

Across TCGA pan-cancer cohorts, CD2BP2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CD2BP2 data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CD2BP2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CD2BP2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and GBM show a favorable association.

LUAD, GBM, and LSCC are the cancer types where CD2BP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	II,III,IV	0.979	0.688	.006	30	view →
GBM	DFS	Median	All	0.456	0.285	.002	17	view →
LSCC	DFS	Median	III,IV	0.626	0.944	.027	4	view →
CCRCC	DFS	Median	II,III,IV	0.843	0.960	.035	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CD2BP2–LUAD (DFS)

Open the LUAD breakdown →